Search results
Results from the WOW.Com Content Network
[16] 2013 saw the company complete its highest number of acquisitions with Lotus Tissue Repair, Inc. (lead compound, ABH001), [17] SARcode Bioscience Inc., [18] with the last being ViroPharma. Shire changed the name of ViroPharma to Shire Viropharma Inc. upon acquisition and on their final day of trading the company was valued at $3.3 billion. [19]
ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease , including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Shire buys ViroPharma for $4.2 billionIrish pharmaceutical company Shire just announced that it will buy ViroPharma for Let's dig into the top stories that could move health care stocks this morning.
Need help? Call us! 800-290-4726 Login / Join. Mail
For premium support please call: 800-290-4726 more ways to reach us
Pleconaril was originally developed by Sanofi-Aventis, and licensed to ViroPharma in 1997. ViroPharma developed it further, and submitted a New Drug Application to the United States Food and Drug Administration (FDA) in 2001. The application was rejected, citing safety concerns; and ViroPharma re-licensed it to Schering-Plough in 2003.
For premium support please call: 800-290-4726 more ways to reach us